Researchers at Shengjing Hospital, led by Li Liu, reveal that altering the metabolism of senescent T cells via mTOR and p38 MAPK pathways enhances cancer immunotherapy. Published on April 9, 2025 in Cell Death Discovery, this breakthrough study offers promising strategies to revitalize immune responses in clinical settings.
Q&A
- What is metabolic reprogramming in T cell senescence?
- How do mTOR and p38 MAPK pathways affect cancer immunotherapy?
- What are the clinical implications of these findings?